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Dengue fever is a mosquito-borne viral disease of global importance with no available antiviral therapy. We assessed the
ability of mycophenolic acid (MPA), a drug currently used as an immunosuppressive agent, to inhibit dengue virus (DV)
antigen expression, RNA replication, and virus production. Pharmacological concentrations of MPA effectively blocked DV
infection, decreasing the percentage of infected cells by 99% and the levels of secreted virus by up to a millionfold. Results
were reproduced with four hepatoma cell lines and different flaviviruses, including a recent West Nile virus isolate.
Experiments were performed to define the stage in the viral lifecycle at which MPA abrogates infection. Early steps in viral
infection, such as viral entry and nucleocapsid uncoating, were not the primary targets of MPA action since its inhibitory
effect was retained when naked DV RNA was transfected directly into cells. Biosynthetic labeling experiments showed that
MPA did not block the initial phase of viral translation but did interfere with viral protein synthesis in the amplification phase.
Quantitative RT-PCR demonstrated that MPA prevented the accumulation of viral positive- and negative-strand RNA as the
infection proceeded. We conclude that MPA inhibits flavivirus infection by preventing synthesis and accumulation of viralKey Words: flavivirus; antiviral; dengue virus; mycopheno
INTRODUCTION
Dengue fever (DF), the most prevalent arthropod-
borne viral disease in humans, is caused by dengue
virus (DV). DV is a single-stranded, positive-polarity, en-
veloped RNA virus with a 10.7-kb genome that is trans-
lated in the cytoplasm as a single polyprotein and
cleaved into three structural and seven nonstructural
proteins. The four serotypes of DV are transmitted to
humans by two species of mosquitoes, Aedes aegypti
and Aedes albopictus. DV is a member of the Flaviviridae
family and is related to the viruses that cause yellow
fever; the Japanese, St. Louis, and West Nile encephali-
tides, and hepatitis C. Infection causes a spectrum of
disease ranging from a debilitating, self-limited illness
(DF) to a life-threatening syndrome (dengue hemorrhagic
fever (DHF)). DV causes disease globally with an esti-
mated 100 million new cases per year (Monath, 1994). At
present, no vaccine exists and treatment is supportive.
Despite its morbidity and mortality, few antiviral thera-
pies have been tested.
Previous studies in our laboratory were directed at char-
acterizing the efficacy and mechanism of agents with anti-
viral activity against DV such as interferons (Diamond et al.,
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2000a). We then initiated a search for other molecules that
could attenuate DV production. Here, we describe the an-
tiviral activity of mycophenolic acid (MPA) against DV infec-
tion of human cells. MPA is a nonnucleoside inhibitor of
inosine monophosphate (IMP) dehydrogenase; by blocking
the synthesis of xanthosine monophosphate, it depletes
intracellular guanosine pools. MPA is used clinically in the
prevention of rejection of transplanted organs (Lipsky,
1996). MPA inhibits to varying degrees the infection of cells
in vitro with several viruses by an unknown mechanism
(Gong et al., 1999; Ichimura and Levy, 1995; Neyts and De
Clercq, 1998). A prior study reported that MPA blocked the
cytopathic effect of YFV in monkey cells (Neyts et al., 1996),
although it had no inhibitory effect on hepatitis GB infection
(Lanford et al., 2001). In this article, we describe in detail the
antiviral properties of MPA against DV infection of human
cells, using as a comparison ribavirin (RBV), a competitive
inhibitor of IMP dehydrogenase that was shown previously
to have a modest antiviral effect against DV in vitro (Koff et
al., 1982). At concentrations well below its use as an im-
munosuppressive agent, MPA potently inhibited DV repli-
cation and protein production. An analysis of the mecha-
nism suggested that MPA inhibited DV infection by prevent-
ing replication of both positive- and negative-strand viral
RNA.
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(Leyssen et al., 2001; Neyts et al., 1996), was assessed
for its ability to inhibit DV type 2 (DV2) infection of human
hepatoma cells. Clinical studies demonstrate DV anti-
gen, DV nucleic acid, and cell death in the liver of pa-
tients infected with DV (Couvelard et al., 1999; Marian-
neau et al., 1998; Rosen et al., 1999); thus, the liver is an
important target of DV infection in vivo. Cell lines of
hepatic origin were used as a suitable and relevant
system for studying DV infection. For the purpose of
comparison, cells were also treated with RBV, an antiviral
agent that modestly inhibits DV infection (Koff et al.,
1982). Treatment of cells with MPA reduced the percent-
age of cells that expressed DV2 antigens in a dose-
dependent manner, as measured by a flow cytometry
assay that detects cells in which DV envelope (E) protein
is expressed intracellularly (Diamond et al., 2000a). MPA
showed an approximately 65-fold greater potency than
RBV (Fig. 1A), with an IC50 (concentration of inhibitor that
reduced the viral antigen expression by 50%) of 0.1 g/ml
(0.31 M). At the clinically therapeutic drug level, MPA
(10 g/ml, 30 M) (Gong et al., 1999; Lipsky, 1996) re-
duced virus production by greater than 6 log, whereas
RBV (25 g/ml, 100 M) (Conner, 1984; Huggins et al.,
1991) decreased it by 3 log. The inhibition was not due to
a toxic effect, as there was no difference in cell viability
by trypan blue exclusion after treatment with MPA at the
doses used (data not shown). At high concentrations,
both MPA (10 g/ml) and RBV (50 g/ml) had a mild
cytostatic effect, as they inhibited cell growth by 50%. In
agreement with previous studies (Koff et al., 1982; Neyts
et al., 1996), the inhibitory effects were completely re-
versed by the addition of 50 g/ml of exogenous
guanosine (data not shown).
To confirm these effects, other cell lines were exposed
to DV2, treated, and analyzed. Three other hepatoma cell
lines (Huh-7, CRL-8024, and HepG2) exhibited a similar
pattern of inhibition, with MPA showing a more potent
antiviral effect than RBV (Table 1). In each cell type, MPA
also showed a greater ability to inhibit the production of
infectious virus (data not shown). Comparable results
were observed with the SW13 human adrenal carcinoma
cell line and BHK21 hamster fibroblasts (data not shown).
To confirm that the inhibitory effects were not limited to
the prototype DV2 strain (16681), we examined the ability
of MPA to inhibit infection with a low-passage DV2 iso-
late, N1047 (Diamond et al., 2000b). When Hep3B cells
were infected with N1047 and then treated with MPA,
expression of viral antigen and production of infectious
virus were significantly blocked (97% reduction in anti-
gen positive cells, 3 log decrease in virus production,
data not shown). Similar results were observed with a
low-passage recent isolate of the Southeast Asian ge-
notype, K0049, in both Hep3B and HepG2 cells (data not
shown). Thus, similar inhibitory effects were seen in
several cell types and with both recent viral isolates and
a prototype strain.
We assessed the antiviral effect of MPA against two
other flaviviruses, yellow fever (YFV) and West Nile
(WNV) viruses. Treatment of Hep3B cells with MPA and
RBV immediately after infection with YFV resulted in a
dose-dependent inhibition of viral antigen and infectious
virus production (Fig. 1B, and data not shown). Again,
MPA was more potent than RBV, as MPA (2 g/ml)
completely blocked YFV production, whereas the highest
concentration of RBV tested was unable to eliminate
virus production. Finally, treatment of murine primary
glial cells with MPA decreased production of WNV by
greater than 100-fold (Fig. 1C).
To assess the kinetics of the effect of MPA and RBV on
DV2 infection, we performed time-course studies. Hep3B
cells were exposed to RBV or MPA either before (24 or
4 h) or after (4 or 24 h) infection with the prototype DV2
strain (Fig. 2A). Pretreatment of Hep3B cells prior to
infection dramatically reduced the percentage of cells
that express viral antigen (MPA, 99% inhibition; RBV,
76–81%) and the production of infectious virions (MPA,
6 log reduction; RBV, 2 log). However, if MPA was
washed out after the cells were exposed to virus, the
inhibitory effect was completely lost. Consistent with
this, when MPA was first added to Hep3B cells 4 or 24 h
after exposure to DV2, viral antigen expression (99 and
94% inhibition, respectively) and infectious virus produc-
tion (6 and 3 log reduction, respectively) were markedly
reduced. Because MPA inhibited the production of infec-
tious virus in Hep3B cells when administered 24 h after
infection, we assessed its activity at later times after
infection (Fig. 2B). Hep3B cells were exposed to DV2 and
allowed to propagate virus for between 24 and 72 h. At
each time point after infection, cells were extensively
washed to remove newly generated virus and exposed to
medium with or without MPA for 48 additional hours, and
then supernatants were harvested for quantification of
infectious virus. Without MPA treatment, viral titers
peaked (36  48  84 h, 3.1  107 PFU/ml) and waned
(72  48  120 h, 8.0  106 PFU/ml). In contrast, in cells
treated with MPA, the inhibition was greatest at the
earlier time points (5800-fold reduction at 72 h and 800-
fold at 84 h), whereas later in infection a smaller effect
was observed (15-fold reduction at 108 h and 3.6-fold
difference at 120 h).
We next investigated the stage in the viral lifecycle at
which MPA blocked infection. Although the antiviral ac-
tion of MPA presumably occurred because of depleted
intracellular guanosine, it was not clear which
guanosine- or GTP-dependent step in the viral lifecycle
(e.g., trafficking, translation, or replication) was most sus-
ceptible. To confirm that MPA did not inhibit the early
steps (attachment, entry, nucleocapsid escape, and un-
coating) of DV infection, an indirect assay was utilized in
which naked viral RNA was transfected into cells (Dia-
mond and Harris, 2001). If MPA inhibited an early step, it
should not significantly inhibit DV replication in cells
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transfected with purified viral RNA. DV2 RNA was iso-
lated under denaturing conditions and transfected into
Huh-7 cells with cationic liposomes. In the presence of
medium alone, significant levels of viral proteins accu-
mulated within the cells, and infectious virus was pro-
duced in cell supernatants (Figs. 3A and 3B). In contrast,
treatment of Huh-7 cells with MPA still virtually abolished
production of viral antigen and infectious progeny after
transfection with DV RNA. Notably, significant levels of
positive-strand viral RNA were detected in the MPA-
treated cells at 4 h posttransfection, confirming that viral
RNA entered these cells but was not able to replicate
efficiently (data not shown). Since the inhibitory effect of
MPA was still observed after transfection of naked viral
RNA, its antiviral action occurred at a step after the
release of the viral genome into the cytoplasm.
Because low intracellular guanosine concentrations
may interfere with the fidelity and processivity of DNA
and RNA polymerases (Crotty et al., 2000, 2001; Huggins,
1989), the effect of MPA on viral RNA accumulation was
assessed. Hep3B cells were exposed to DV2, treated
with medium, RBV, or MPA, and harvested for RNA de-
termination by an asymmetric, quantitative, competitive
TABLE 1
Effect of RBV and MPA on DV2 Infection in Hepatoma Cell Lines
Cell linea
RBV IC50
(M)b
MPA IC50
(M)
Hep3B 20 0.3
HepG2 60 3
CRL-8024 100 1.2
Huh-7 40 1.9
a Human hepatoma cells were exposed to DV2 (strain 16681), incu-
bated with increasing concentrations of RBV or MPA, cultured for 72 h,
harvested, and subjected to flow cytometry with mAbs against the E
protein.
b The IC50 was defined as the concentration of RBV or MPA that
inhibited expression of DV antigen in 50% of the infected cells relative
to a medium-treated control. The data reflect the average of at least two
independent experiments per cell line, and the standard deviations for
the dose-response curves ranged from 5 to 25%.
FIG. 1. (A) Effect of MPA and RBV on generation of DV2 antigen-
positive cells. Hep3B cells were exposed to DV2 and incubated with
increasing concentrations of MPA or RBV. Seventy-two hours later, cells
were subjected to indirect immunofluorescent flow cytometry. The
results are expressed as the percentage of cells that express the E
protein of DV2 relative to the untreated (medium) control. The data are
the average of three experiments (n  3) and the error bars represent
the standard deviations. (B) Effect of RBV and MPA on yields of DV2 and
YFV from Hep3B cells. Cells were infected as described above with the
exception that YFV was also used. Seventy-two hours after infection
supernatants were harvested for viral plaque assays. The plaque assay
data are expressed as the number of plaque forming units per milliliter
(PFU/ml) based on cytopathic effect in BHK21 cells (n  3). (C) Effect
of MPA on WNV infection in primary glial cells. After infection, cells
were incubated with increasing concentrations of MPA. Seventy-two
hours later, supernatants were harvested for viral plaque assays in
Vero cells. The data are expressed as above and represents one of two
independent experiments.
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FIG. 2. (A) Time course of the effect of RBV and MPA treatment on DV2 infection. Hep3B cells were exposed to DV2 and incubated for 72 h. Cells
were exposed to RBV (10 g/ml) or MPA (10 g/ml) either prior to (“() 24 or () 4 h”) or after (“() 4 or () 24 h”) incubation with virus. WASH indicates
that the inhibitor was removed by the washing protocol after infection but was not added back. Cells that were treated with medium alone yielded
1.9  106  0.9  105 PFU/ml. After infection, cell supernatants were harvested and assayed by viral plaque assay as described in Fig. 1 (n  2).
Asterisks are indicated when no viral plaques were detected (limit of detection  10 PFU/ml). A diagram of the addition, washing, and readdition of
RBV and MPA is also depicted. The X indicates that inhibitor was not added back after infection. (B) Effect of MPA on DV2 production at later stages
of infection. Hep3B cells were exposed to DV2. After washing, cells were incubated for the time period indicated (24, 36, 48, 60, or 72 h) and then
treated with either medium or MPA (10 g/ml). Forty-eight hours later, cell supernatants were harvested for viral plaque assays as described in Fig.
1 (n  2).
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RT-PCR assay (Diamond et al., 2000a,b). At 48 h postin-
fection, treatment of cells with RBV or MPA reduced
positive-strand viral RNA 10- to 200-fold and negative-
strand viral RNA 10- to 1000-fold reduction (Fig. 4A).
Kinetic analysis revealed that at early time points (2, 6,
and 12 h postinfection), MPA did not appear to affect the
steady-state level of the positive or negative strands (Fig.
4B). The low level of viral RNA at these time points likely
reflected that from the input virus. After 12 h, the medium-
treated cells manifested an abrupt logarithmic increase
in positive- and negative-strand viral RNA. In contrast, no
dramatic increase or rapid decrease was observed in
the steady-state levels of positive- or negative-strand
viral RNA in the MPA-treated cells over time.
Because MPA blocked the accumulation but did not
accelerate the degradation of viral RNA in cells infected
with virus or transfected with viral RNA, two possible
mechanisms were hypothesized: MPA inhibited the
translation of the infectious viral RNA (by interfering with
GTP-dependent steps in translation) or MPA impeded the
synthesis of viral RNA. To investigate whether it affected
input-strand translation, Hep3B cells were infected with
DV, treated with medium or medium plus MPA for 6, 9, 12,
15, or 18 h, and then biosynthetically labeled for 20 min.
Synthesis of viral proteins was detected in lysates after
9 h in cells that were treated with medium but not in
uninfected cells or cells treated with MPA (Fig. 5A). The
identity of DV NS5 and NS3 was confirmed by either
Western blot (Fig. 5B) or by comparison with gels con-
taining lysates of virally infected cells at later times (24
FIG. 3. Transfection of Huh-7 cells with DV2 RNA. Cells were transfected with equivalent amounts of purified DV RNA and incubated in the presence
or absence of MPA. Forty-eight hours after transfection, cells were harvested and processed for antigen expression (A) or virus production (B) as
described in Fig. 1. The data are representative of two independent experiments.
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h) in the course of infection. One interpretation of these
data was that MPA blocked DV infection by preventing
translation of the input strand of DV RNA.
To further investigate the stage at which inhibition
occurred, experiments were designed so that translation
of input-strand viral RNA could be observed at very early
time points after entry yet prior to replication of viral RNA.
BHK21 cells were infected with wild-type (16681) DV at a
high m.o.i. to generate a large pool of translatable viral
RNA at early time points. Immediately prior to biosyn-
thetic labeling, excess (175 mM) NaCl was added; this
treatment reduces the rate of synthesis of cellular pro-
teins more than viral proteins (Erdei, 1981; Schrader and
Westaway, 1990; Svitkin et al., 1978). In contrast to the 6-
FIG. 4. (A) Effect of RBV and MPA on the levels of positive and negative strand of DV2 RNA. Hep3B cells were exposed to DV2 (strain 16681) and
then incubated with medium, RBV (10 g/ml), or MPA (10 g/ml). Seventy-two hours later, cells were harvested, RNA was isolated, and quantitative
asymmetric RT-PCR was performed. The amount of viral RNA was determined from the competitor concentration that produced competitor and DV
bands of equal intensity. One representative experiment of two is shown. (B) Prospective time course of the effect of MPA on DV2 RNA production.
Hep3B cells were infected with DV2 (strain 16681) at an m.o.i. of 3. After incubating with MPA or medium for the indicated times (2, 6, 12, 24, 26, 48,
or 72 h), cells were harvested for viral RNA determination by asymmetric, competitive RT-PCR.
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and 9-h time points in Hep3B cells (Fig. 5A), in BHK21
cells in the absence of significant cellular protein syn-
thesis, translation of NS5 was detected in both medium-
and MPA-treated cells at 2, 4, and 6 h after infection (Fig.
5C). However, by 8 h after infection, whereas there was
a noticeable increase in synthesis of NS5 in medium-
treated cells, a marked decrease was observed in the
MPA-treated cells. This decrease was reversed by the
addition of excess guanosine (Fig. 5C). These early time-
course translation studies suggested that MPA did not
prevent translation of the infectious DV RNA.
Because MPA did not inhibit the early phase of viral
translation, we hypothesized that it must directly inhibit
viral replication, by blocking the synthesis of negative-
and/or positive-strand viral RNA. Studies were repeated
at early time points after infection with a more sensitive
and quantitative real-time RT-PCR (Houng et al., 2001) to
distinguish small increases in positive- and negative-
strand viral RNA replication. At the earliest time points, a
higher m.o.i. was used to enhance sensitivity of detec-
tion. No increases in viral RNA were observed at 2 and
4 h after infection (m.o.i.  100) in the medium and
MPA-treated cells. However, reproducible increases in
negative and positive viral RNA were observed at 6 h
after infection only in the medium-treated cells (Figs. 6A
and 6B). To distinguish whether MPA blocked negative-
and/or positive-strand viral RNA synthesis, the effect of
MPA was measured at a point during the course of
infection when both strands would be replicating. BHK
cells were infected with DV (m.o.i.  3), incubated for
12 h to generate a pool of actively replicating viral RNA,
and then treated with medium or MPA. At several time
points after treatment, the levels of positive- and nega-
tive-strand viral RNA were determined by real-time RT-
PCR (Figs. 6C and 6D). Significantly, treatment with MPA
resulted in an abrupt cessation in the accumulation of
both positive- and negative-strand viral RNA.
DISCUSSION
This article establishes that infection of human cells in
vitro by DV is completely prevented by pharmacologically
relevant concentrations of MPA, a nonnucleoside inhib-
itor of IMP dehydrogenase. Using quantitative RT-PCR,
biosynthetic labeling, RNA transfection, flow cytometry,
and viral plaque assays, we demonstrated that MPA
potently inhibited DV infection by significantly reducing
the levels of viral RNA, intracellular viral antigen, and
infectious progeny virus. The inhibitory effect of MPA
was reversed by the addition of exogenous guanosine
and was not due to cellular toxicity. Time-course and
washout studies revealed that the antiviral effect re-
quired the continued presence of MPA. When the mech-
anism of inhibition was analyzed, we found that although
the later phases of viral protein synthesis were inhibited,
FIG. 5. (A) Effect of MPA on viral protein translation in Hep3B cells. Hep3B cells were either not infected (U) or infected with DV2 in the presence
of medium or MPA. After the indicated times postinfection (6, 9, 12, 15, and 18 h), cells were labeled biosynthetically with 35S for 20 min. After washing,
cells were lysed, and the proteins resolved by 8% SDS–PAGE and autoradiography. The migration of viral proteins (arrows) was confirmed by Western
blot (B) and with labeled markers. (B) Immunoblot analysis of Hep3B cells infected with DV2. Hep3B cells were infected with DV2 in the presence
of medium or medium plus MPA. After 24 h, cells were harvested and protein extracts were analyzed by SDS–PAGE. Proteins were transferred to a
nitrocellulose membrane and probed with polyclonal anti-NS5 antibodies. (C) Effect of MPA on translation of NS5 at early time points after infection
in BHK21 cells. BHK21 cells were pretreated for 6 h with media or MPA (2.5 g/ml). Subsequently, cells were mock-infected (lanes marked with U)
or infected with DV2 in the presence or absence of MPA. At the indicated time points after infection, cells were labeled for 30 min with 35S in the
presence of 175 mM excess NaCl as described under Materials and Methods. Cells were detached and lysed in SDS–sample buffer, and the proteins
were resolved by 7% SDS–PAGE and autoradiography. The migration of NS5 and labeled markers is indicated.
217MYCOPHENOLIC ACID INHIBITS DENGUE VIRUS INFECTION
MPA did not block translation of the input strand of viral
RNA but instead prevented synthesis of viral RNA.
MPA is currently used as an immunosuppressive
agent to prevent organ rejection in transplantation; in this
capacity, it is believed to act by blocking T cell prolifer-
ation (Allison and Eugui, 1993). Previous studies have
reported that MPA inhibited in vitro infection by several
viruses (Gong et al., 1999; Ichimura and Levy, 1995; Neyts
and De Clercq, 1998; Neyts et al., 1996) in a guanosine-
dependent manner. However, there were no prior studies
with MPA and DV infection. Our data show convincingly
that MPA is a potent anti-DV agent that can abrogate a
new infection or attenuate an existing infection. More-
over, preliminary studies demonstrated a significant in-
hibitory effect of MPA on infection in primary glial cells by
low-passage WNV isolates. Although additional studies
must be performed, these investigations suggest that
MPA may have broad antiviral properties against flavivi-
ruses. Experiments are planned to test the efficacy of
MPA against WNV and DV infection in a mouse model of
disease.
Because the inhibitory effects of MPA are reversed by
guanosine, its antiviral activity depends on its capacity to
deplete intracellular guanosine levels. MPA likely does
not act as a viral mutagen; it is not a nucleoside analog
and thus cannot incorporate into the nascent RNA
strand. Here, the stage at which MPA inhibited DV infec-
tion was examined; no prior study has described which
FIG. 6. Effect of MPA on the accumulation of positive- and negative-strand DV RNA at early times postinfection. (A and B) Early time course (0 to
8 h) of positive- (A) and negative- (B) strand DV RNA accumulation in BHK21 cells using Taq-Man fluorogenic quantitative RT-PCR. Cells were treated
with medium or MPA 18 h prior to infection (m.o.i.  100) and harvested at the indicated time after infection. Samples were run in triplicate and reflect
the average of two different experiments. The absolute amount of viral RNA was determined using standards that were measured by spectropho-
tometer. (C and D) Effect of MPA on positive- (C) and negative- (D) strand DV RNA accumulation in DV-infected BHK21 cells. Cells were infected (m.o.i.
 3) for 12 h and then exposed to medium or MPA (arrow). After the indicated times, cells were harvested, and RNA was measured by real-time
fluorogenic RT-PCR. Samples were run in duplicate and reflect the average of two different experiments.
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guanosine-dependent step in the viral lifecycle is limited
by MPA. In DV-infected BHK21 cells, translation of input-
strand viral RNA was observed at very early time points
in both medium- and MPA-treated cells using a high
dose of infectious virus and conditions that reduced host
cell protein synthesis. A sensitive real-time RT-PCR as-
say demonstrated that translation of NS5 clearly pre-
ceded replication of viral RNA in medium-treated cells,
and that neither negative- nor positive-strand viral RNA
accumulated in MPA-treated cells. Collectively, these ex-
periments suggest that MPA blocks DV infection by pre-
venting replication of viral RNA. Studies are underway to
determine the exact mechanism, but at this time we
hypothesize that low intracellular guanosine levels ad-
versely affect the processivity of the viral replicase.
RBV has broad-spectrum antiviral activity in vitro and
in vivo against a number of viruses. However, as an
antiviral agent against flaviviruses, RBV has modest in-
hibitory activity. High doses of RBV were required to
inhibit WNV replication in human neural cells (Jordan et
al., 2000) and YFV infection in monkey kidney cells (Neyts
et al., 1996). In prior experiments with DV in vitro, high
concentrations of RBV (100 M) were required to reduce
viral titer in monkey kidney cells (Koff et al., 1982). Our
data in human hepatoma cells are consistent with this,
as we observed a significant inhibitory effect only at the
highest (100 M) concentrations used. The limited in vivo
experience with DV has not been auspicious, as RBV
failed to attenuate DV infection in a murine intracerebral
inoculation model (Koff et al., 1983) and a rhesus monkey
model (Malinoski et al., 1990).
Recent studies suggest that the pathogenesis of DHF
may be explained by an enhanced viremia (Vaughn et al.,
2000) coupled with an unrestrained immune system re-
sponse with extensive T lymphocyte activation and pro-
duction of inflammatory cytokines (Rothman and Ennis,
1999). The data we present in this article suggest that at
clinically relevant concentrations MPA potently inhibits
DV infection by blocking replication of viral RNA. Given
the immunopathogenesis of DHF, it is intriguing to con-
sider therapeutic trials with MPA, a drug that efficiently
prevents and attenuates viral translation but also, as an
immunosuppressive, blunts some of the proliferative and
cytokine responses of the immune system. Independent
of its clinical utility as an antiviral agent, by specifically
disrupting flavivirus replication, MPA may become a use-
ful tool to disrupt steps in the viral lifecycle that are
coupled to replication.
MATERIALS AND METHODS
Reagents, cell culture, antibodies, and viruses
MPA, RBV, and guanosine were purchased commer-
cially (Sigma Chemical Co., St. Louis, MO). Human cells
were cultured in RPMI 1640 as described previously
(Diamond et al., 2000a) and obtained from the following
sources: HepG2 hepatoma cells (the American Type Cul-
ture Collection (ATCC), Rockville, MD), Hep3B hepatoma
cells (a gift of J. Boothroyd, Palo Alto, CA), CRL-8024
hepatoma cells (ATCC), and Huh-7 hepatoma cells (a gift
of A. Dasgupta, Los Angeles, CA). BHK21-15 hamster
kidney cells were maintained in -modified Eagle’s me-
dia, and C6/36 mosquito cells were cultured in Leibo-
vitz’s L15 media as described (Diamond et al., 2000a).
Glial cells were isolated from the cerebral cortex of
neonatal C57BL/6 mice according to a published proto-
col (Goslin and Banker, 1992). These cells were main-
tained in Eagle’s media supplemented with 20% fetal calf
serum and used after one passage. Hybridoma cells that
produce monoclonal antibodies against the envelope
proteins of DV (3H5-1, anti-DV2; 5D4-11, anti-DV3; 4G2,
antiflavivirus) were obtained (ATCC) and cultured in
DMEM (Diamond et al., 2000b). DV2 strains used in-
cluded a prototype DHF strain (16681) from Thailand
(Russell and Nisalak, 1967) and a recent DF isolate
(N1047, passage 2) from Nicaragua (Balmaseda et al.,
1999; Diamond et al., 2000b). The YF virus was derived
from the 17D vaccine strain. The WNV strain (3000.0259,
passage 1) was isolated from a mosquito in New York in
2000 (Ebel et al., 2001) and obtained from Dr. Laura
Kramer (Albany, NY).
Plaque and flow cytometric assays
Virus production was titered by plaque assays as
described previously (Diamond et al., 2000a). For the
experiments in which RBV and MPA were used, after a
2-h exposure to virus, BHK21 cells were washed four
times with medium prior to the addition of the agarose
overlay. To determine the percentage of cells that ex-
pressed viral antigen, flow cytometric analysis was per-
formed as described (Diamond et al., 2000a).
Cell infection with virus
Cells were infected with DV2, YF, or WNV; briefly, virus
was added to monolayers at a given multiplicity of infec-
tion (m.o.i.) and incubated at 37°C for 2 h (Diamond et al.,
2000a). Subsequently, the cells were washed four times
to remove residual unbound virus. In some experiments,
cells were treated with a given concentration of RBV or
MPA prior to, during, or after exposure to DV2. In the
early time-course studies, RBV or MPA was added to
cells before and/or after DV infection. For some experi-
ments, guanosine (50 g/ml) was added to the cells after
infection with DV2. Supernatants and cells were har-
vested 72 h after infection for quantitation of viral anti-
gen, positive- and negative-strand RNA, and infectious
virion. In the late time-course experiments, cells were
infected with DV2, incubated for a given time (24, 36, 48,
60, or 72 h), extensively washed, and then in some cases
incubated with MPA (10 g/ml). Forty-eight hours after
219MYCOPHENOLIC ACID INHIBITS DENGUE VIRUS INFECTION
this addition, cell supernatants were harvested for virus
titration by plaque assay.
Cell transfection with RNA
Huh-7 cells were transfected with purified RNA using
cationic liposomes. RNA was purified from DV2 viral
supernatants (3  108 PFU) using the RNEasy Mini Kit
(Qiagen, Valencia, CA) and eluted in RNAse-free ddH2O.
The cationic lipid reagent DMRIE-C was used according
to the manufacturers’ instructions (Gibco-BRL). Briefly,
Huh-7 cells were washed in Opti-MEM I medium (Gibco-
BRL) and plated (2  105 cells/well) in a 12-well plate.
Liposomes were prepared, and immediately after, puri-
fied DV2 RNA was added; the RNA-liposome suspension
was added to Huh-7 cells in the presence or absence of
MPA (10 g/ml) for 6 h at 37°C. Subsequently, the lipo-
some suspension was removed, and complete medium
was added with or without MPA. Cells and supernatants
were harvested 72 h later for plaque assay, flow cyto-
metric analysis, and viral RNA determination.
Quantitative RT-PCR
For experiments with Huh-7 cells, positive- and nega-
tive-strand DV RNA was quantitated using a competitive
RT-PCR assay (Diamond et al., 2000a). We observe a
small yet reproducible amount of negative-strand viral
RNA in our input virus samples. This low level is present
after virion purification by sucrose gradient sedimenta-
tion and may reflect viral particles that contain fragments
of negative-strand viral RNA (Novak and Kirkegaard,
1991) or residual membrane fragments with associated
negative-strand RNA that cosediment with virions. For
experiments with BHK21 cells, positive- and negative-
strand viral RNA was measured by real-time PCR using
the Taq-Man RT-PCR buffer system and an ABI 7000
Sequence Detection System (Applied Biosystems, Foster
City, CA). To quantitate DV, two primers and a probe were
generated using a sequence in the DV2 3 noncoding
region according to a previously published protocol
(Houng et al., 2001).
Biosynthetic labeling
For biosynthetic labeling in Huh-7 cells, published
protocols were modified (Baxt and Bablanian, 1976; Baxt
et al., 1977). Hep3B cells were plated (0.7  105) in
48-well tissue culture plates, infected with DV2 (m.o.i. of
200), and treated with medium or medium plus MPA (10
g/ml) for 5, 8, 11, 14, and 17 h. Cells were washed three
times in RPMI cysteine methionine (cysmet) me-
dium supplemented with 5% dialyzed FBS in the pres-
ence or absence of MPA and incubated for 1 h. Subse-
quently, 0.1 mCi of [35S]cys-met was added for 20 min.
Cells were then washed three times in PBS at 4°C,
detached, pelleted, and lysed in 0.2 ml lysis buffer (1%
Triton X-100, 140 mM NaCl, 25 mM Tris–HCl pH 7.8,
0.025% NaN3, 1 mM phenylmethylsulfonylfluoride, 2
mg/ml iodacetamide, 0.2 TIU/ml aprotinin, and 0.5% bo-
vine hemoglobin) on ice. After 15 min, the lysate was
clarified by centrifugation at 10,000 g (10 min at 4°C).
SDS sample buffer with 5% -mercaptoethanol was
added to an aliquot (40 l) of the clarified lysate and
subjected to 7% SDS–PAGE and autoradiography. For
biosynthetic labeling in BHK21 cells, a protocol was used
that maximized the translation of viral proteins at early
time points (Erdei, 1981; Schrader and Westaway, 1990;
Svitkin et al., 1978). Cells (1.5  105) were plated in
24-well plates and pretreated overnight in media or MPA
(2.5 g/ml) and infected at an m.o.i. of 100. One hour
prior to labeling, cells were washed and incubated with
RPMI cysmet medium. Twenty minutes prior to label-
ing, 175 mM excess NaCl was added. Cells were labeled
for 30 min with 0.075 mCi of [35S]cys-met and then de-
tached. After washing by centrifugation, cell pellets were
lysed in 50 l SDS sample buffer supplemented with 5%
-mercaptoethanol and 2 M urea, boiled, and electro-
phoresed.
Immunoblot analysis
Hep3B cells (3.0  105) were infected with DV2 (m.o.i.
of 100) and treated with medium or medium plus MPA (10
g/ml) for 24 h. Cells were then washed three times in
PBS, detached, and pelleted. Cell lysates were prepared
by freeze-thawing once and resuspended in 6 SDS
sample buffer. One-half of the lysate was loaded per
lane, subjected to SDS–PAGE and transferred to nitro-
cellulose (MSI, Westborough, MA). The membrane was
blocked with 5% nonfat dry milk, probed with mouse
polyclonal anti-NS5 antibodies (1:1000), washed five
times with PBS-Tween 20 (0.1% v/v), incubated with goat
anti-mouse secondary antibody conjugated to horserad-
ish peroxidase (Sigma Chemical Co.) at a dilution of
1:2000, and washed five times with PBS–Tween 20. After
incubation with the substrate Luminol (Sigma Chemical
Co.), NS5 was visualized by autoradiography.
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